Amneal's $7 Million Launch: The Biosimilar Thesis Just Became a P&L Line Item

A clean beat, a raised guide and a fresh 90-day high — while free cash flow runs negative and the equity has already doubled on price-to-revenue

AMRX · Earnings Call · 2026-11-03

The quarter the story changed shape

Amneal's Q3 was, on the surface, the cleanest quarter in years. Revenue of $863 million, up 10%; adjusted EBITDA of $207 million, up 30%; adjusted EPS $0.26, up 53%; and a third consecutive raise to 2026 guidance — revenue midpoint up $50 million to $3.15–$3.25 billion, EBITDA up $43 million to $800–$815 million. The tape agrees: the stock is up 16.9% over 90 trading days and sits 6% below its October 30 peak of $21.51, after a decade in which it spent most of its life climbing out of a 60.6% drawdown from the 2015 high.

But the beat isn't the story. The story is what the vocabulary did.

For six quarters, Amneal's language was dominated by one idea: vertical integration in biosimilars. "vertical integration" was the highest-momentum keyword in Q4 2025; "biosimilar leader" ranked second in Q2 2026; "combined company", "Kashiv BioSciences", "large molecule" and "competitive landscape" crowded the top of the list. This quarter, almost none of that vocabulary survives at the top. In its place sit end-to-end capability, patent settlement, a modestly ranked Kashiv acquisition — and a new number one at the highest momentum reading in the company's recent record: complex generics.

That isn't a strategy change. It's the attention catching up to a strategy that already happened. The deal closed in August; vertical integration is no longer a thesis, it's a balance-sheet line. Chirag in April: “partnering versus full economics or vertically means vertically integrated. Yes, it is complex.” — Chirag Patel, CEO · 2026-04-22 That question has now been answered with a purchase price, and the market's editors have moved on to execution.

Lanreotide: from option value to arithmetic

Nowhere is the shift clearer than lanreotide. In April and July, analysts grilled management on gating items and FDA timing; in July Chirag hedged: “So, lanreotide is on its way... we have included some of the forecast number, but not probably the market” — Chirag Patel, Co-Chief Executive Officer · 2026-07-30 — with Tasos jumping in to call it "very conservative."

Last night it became a number. Roughly $7 million of revenue from a late-September launch, with the CFO's forward marker: “You can expect multiple times of that in Q4” — Tasos Konidaris, Chief Financial Officer (CFO) · 2026-11-03 — against a stated 30–40% share ambition and a two-strength supplement being filed this quarter, with launch in the second half of 2027. Worth pinning the detail: “90% of the sales are in the 120 mg strength.” — Chintu Patel, Chief Operating Officer (COO) · 2026-11-03 That single approval covers most of the market, which is why the ramp can start before the other strengths land. Lanreotide is also the cleanest proof of the Kashiv logic — it originated at Kashiv, and Amneal now keeps 100% of the profit instead of sharing it. Iohexol follows the same script: immaterial in 2026, a "key growth driver" in 2027, full SKU basket now filed.

The cash catch

Here is where I'd push back on the enthusiasm. The income statement is compounding; the cash flow statement is not. The latest filed quarter showed free cash flow of -$62 million against net income of +$70 million — a 218% year-over-year deterioration — with free cash flow margin at -7.8%. Management cut 2026 operating cash flow guidance by $25 million at the midpoint to $325–$375 million, and the explanation is entirely working capital: “The operating cash flow adjustment is driven by timing and reflects our decision to increase internal finished goods inventory to satisfy strong revenue demand” — Tasos Konidaris, Chief Financial Officer (CFO) · 2026-11-03, plus collections slipping into Q1 2027.

Building inventory into demand is defensible. But it lands next to a leverage step-up: net leverage was 3.0x post-Kashiv, is guided to 3.6x at year-end, and only gets below 3x by 2028. Effective net cash is -$2.5 billion, $1.2 billion worse year-over-year. And the equity has already re-rated for the outcome: price-to-revenue went from roughly 0.9x to 1.8x, while price-to-FCF is 59.9x. Paying 60x trailing free cash flow for a company that just told you conversion is worsening is the trade being offered.

There is no such thing as leaky buckets on these products. These are needed products. Some goes down, some goes up, 300 products portfolio. Now, we are predicting that our base business will grow.
Chirag Patel, Chief Executive Officer (CEO) · 2026-11-03

That is the most load-bearing claim on the call, because it's what makes the 2030 bridge credible — $3.1–3.2 billion today to $4.3–4.5 billion, of which the April framing put $1–1.3 billion in biosimilars. And the pieces matter: AvKARE fell 17% as guided (a "reset" first flagged in February and now delivered), so the entire burden falls on affordable medicines (+19%) and specialty (+20%). Which raises an awkward detail — R&D fell 19% year-over-year to $39 million, a 4.9% of revenue, while management promises a multi-year filing cadence and an accelerated 2030 revenue trajectory.

What the tape, and the silence, say

Tariffs. In July an analyst asked directly about tariff headlines and Chirag leaned on the U.S. footprint: “As you know, Amneal has a very vast manufacturing network in the United States.” — Chirag Patel, Co-Chief Executive Officer · 2026-07-30 This quarter: zero tariff mentions, in the script or the Q&A — even as tariff refund stays a live, monetized theme across this week's reporters, with AOS, HSIC, ORLY and KTB all booking IEEPA refunds. Amneal makes roughly two-thirds of its manufacturing value domestically and has disclosed no such benefit. Silence isn't a denial, but with the stock where it is, "we didn't get that" deserves a question in February.

The one genuinely global wave Amneal is riding is GLP-1. The Pfizer collaboration is a real asset — 12 Pfizer visitors toured the facilities, capacity is described as fully digitized — and the supplier ecosystem is echoing it (ATR flagged GLP-1 elastomer components; STVN called out a GLP headwind). Note, though, a quiet inconsistency: the prepared remarks say the new drug-substance and drug-product plants "remain on track for 2028", while in Q&A Chintu said "we will complete the construction in late 2028 to 2029." A one-year slip in a $400–500 million benefit narrative is the kind of thing that never appears in an EBITDA guide.

Strip it back: the shares are being priced as a vertically integrated biosimilar platform. The P&L still reads as a complex-generics launch machine with a working-capital hole and a leverage ratio going the wrong way. That gap — not the lanreotide number — is what the next two quarters will settle.